IFNA1 and neoplasm: Despite that the overall immune dysfunction may lead to decreased IFN levels in tumors, persistent inflammation increased in FR‒ HCCs may drive transcriptomics or epigenetic changes in tumor cells to maintain chronic IFN stimulation, promoting disease progression or resistance programs.